---
title: "AtriCure, Inc. 2026: Revenue $153.6M, EPS $0.18— 10-Q Summary"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293960284.md"
description: "AtriCure reported Q2 2026 revenue of $153.6M, up 12.8% YoY, and returned to profitability with diluted EPS of $0.18 versus a loss in the prior year. Growth was driven by strong U.S. demand and improved product mix. Minimally invasive ablation procedures declined as physicians adopted pulsed field ablation catheters. The company secured CE marks for AtriClip devices and continues active R&D programs."
datetime: "2026-07-27T17:11:02.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293960284.md)
  - [en](https://longbridge.com/en/news/293960284.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293960284.md)
---

# AtriCure, Inc. 2026: Revenue $153.6M, EPS $0.18— 10-Q Summary

AtriCure, Inc. reported 2026 quarter results with revenue of $153.6M, up 12.8% from $136.14M a year earlier, and diluted EPS of $0.18 compared with ($0.13) in the prior-year quarter as the company returned to net income of $8.96M versus a loss of ($6.19M).

**Financial Highlights**

Metric

Current quarter

Prior year quarter

YoY change

Revenue¹

$153.6M

$136.14M

12.8%

Net income²

$8.96M

($6.19M)

244.7%

Diluted EPS³

$0.18

($0.13)

238.5%

_¹ Reported as “Revenue”. ² Reported as “Net income (loss)”. ³ Reported as “Diluted net income (loss) per share”._

**Business Highlights**

-   Revenue growth of about 13% was driven by strong U.S. demand and improvements in product mix.
-   Minimally invasive ablation procedures declined about 24% as physicians increasingly adopt pulsed field ablation (PFA) catheters, shifting procedure mix.
-   Brand momentum continued for pain management, open ablation (EnCompass) and appendage devices (AtriClip FLEX/PRO-Mini).
-   Regulatory and product progress included CE mark clearance for AtriClip FLEX-Mini and PRO-Mini; R&D and clinical programs such as LeAAPS and BoxX-NoAF remain active.
-   Expanded training and adoption support — including virtual proctoring, CADet simulation and global streaming — to scale physician education.

Original SEC Filing: AtriCure, Inc. \[ ATRC \] - 10-Q - Jul. 27, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [ATRC.US](https://longbridge.com/en/quote/ATRC.US.md)

## Related News & Research

- [AtriCure Q2 net income turns to USD 8.96 million; revenue rises 12.8% to USD 153.6 million year over year](https://longbridge.com/en/news/293959967.md)
- [AtriCure Chief Scientific Officer Vinayak Doraiswamy disposes of $233,280 in common shares](https://longbridge.com/en/news/294417197.md)
- [Board Member At AtriCure Exercises Options Worth $491K](https://longbridge.com/en/news/294530665.md)
- [AtriCure to join Needham Virtual MedTech & Diagnostics investor conference](https://longbridge.com/en/news/293928171.md)
- [Atricure Still Faces Broad, Evolving Risks Despite No Material Changes in 2025 10-K Disclosures](https://longbridge.com/en/news/294017350.md)